Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson’s Disease
Neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) are both characterized by pathogenic protein aggregates that correlate with the progressive degeneration of neurons and the loss of behavioral functions. Both diseases lack biomarkers for diagnosis an...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/16/9299 |
| _version_ | 1797444716081446912 |
|---|---|
| author | Rekha Raghunathan Kathleen Turajane Li Chin Wong |
| author_facet | Rekha Raghunathan Kathleen Turajane Li Chin Wong |
| author_sort | Rekha Raghunathan |
| collection | DOAJ |
| description | Neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) are both characterized by pathogenic protein aggregates that correlate with the progressive degeneration of neurons and the loss of behavioral functions. Both diseases lack biomarkers for diagnosis and treatment efficacy. Proteomics is an unbiased quantitative tool capable of the high throughput quantitation of thousands of proteins from minimal sample volumes. We review recent proteomic studies in human tissues, plasma, cerebrospinal fluid (CSF), and exosomes in ALS and PD that identify proteins with potential utility as biomarkers. Further, we review disease-related post-translational modifications in key proteins TDP43 in ALS and α-synuclein in PD studies, which may serve as biomarkers. We compare relative and absolute quantitative proteomic approaches in key biomarker studies in ALS and PD and discuss recent technological advancements which may identify suitable biomarkers for the early-diagnosis treatment efficacy of these diseases. |
| first_indexed | 2024-03-09T13:16:30Z |
| format | Article |
| id | doaj.art-7c1d9675467a443fb875b8a977dd2903 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T13:16:30Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-7c1d9675467a443fb875b8a977dd29032023-11-30T21:35:47ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-08-012316929910.3390/ijms23169299Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson’s DiseaseRekha Raghunathan0Kathleen Turajane1Li Chin Wong2Bioanalytical and Biomarker, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company, New York, NY 10016, USABioanalytical and Biomarker, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company, New York, NY 10016, USABioanalytical and Biomarker, Prevail Therapeutics, a Wholly Owned Subsidiary of Eli Lilly and Company, New York, NY 10016, USANeurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) are both characterized by pathogenic protein aggregates that correlate with the progressive degeneration of neurons and the loss of behavioral functions. Both diseases lack biomarkers for diagnosis and treatment efficacy. Proteomics is an unbiased quantitative tool capable of the high throughput quantitation of thousands of proteins from minimal sample volumes. We review recent proteomic studies in human tissues, plasma, cerebrospinal fluid (CSF), and exosomes in ALS and PD that identify proteins with potential utility as biomarkers. Further, we review disease-related post-translational modifications in key proteins TDP43 in ALS and α-synuclein in PD studies, which may serve as biomarkers. We compare relative and absolute quantitative proteomic approaches in key biomarker studies in ALS and PD and discuss recent technological advancements which may identify suitable biomarkers for the early-diagnosis treatment efficacy of these diseases.https://www.mdpi.com/1422-0067/23/16/9299biomarkersneurodegenerationALSPDTDP43proteomics |
| spellingShingle | Rekha Raghunathan Kathleen Turajane Li Chin Wong Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson’s Disease International Journal of Molecular Sciences biomarkers neurodegeneration ALS PD TDP43 proteomics |
| title | Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson’s Disease |
| title_full | Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson’s Disease |
| title_fullStr | Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson’s Disease |
| title_full_unstemmed | Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson’s Disease |
| title_short | Biomarkers in Neurodegenerative Diseases: Proteomics Spotlight on ALS and Parkinson’s Disease |
| title_sort | biomarkers in neurodegenerative diseases proteomics spotlight on als and parkinson s disease |
| topic | biomarkers neurodegeneration ALS PD TDP43 proteomics |
| url | https://www.mdpi.com/1422-0067/23/16/9299 |
| work_keys_str_mv | AT rekharaghunathan biomarkersinneurodegenerativediseasesproteomicsspotlightonalsandparkinsonsdisease AT kathleenturajane biomarkersinneurodegenerativediseasesproteomicsspotlightonalsandparkinsonsdisease AT lichinwong biomarkersinneurodegenerativediseasesproteomicsspotlightonalsandparkinsonsdisease |